Sharemaestro company-news research for Arvinas Inc (ARVN), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest ARVN news and sentiment
Arvinas Inc
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
14 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone69/100
→
Published 30-day score51/100
Latest source headline
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
GlobeNewswire · 07 Oct 2026 11:00
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
14 current stories are mapped specifically to ARVN.
What limits the score
Only 2 publishers currently contribute to the measured read.
The stories agree, but freshness-weighted evidence is only 0.049.
Confidence is 18/100, below the threshold for a firm score.
51/100
News scoreEarly balanced news score
18/100
Confidencethin evidence
96%/100
Company news14 company stories
94/100
Story agreement6/100 difference
News history
Daily score and story count over 30 days
17 Sep02 Oct16 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence1
0.049 after freshness weightingSource breadth40
2 independent publishersCompany relevance96
share tied directly to this companyFreshness6
recency-weighted evidenceAgreement94
how closely stories agreePublisher mix28
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks16 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202653USD 7.64+3.1%
02 Oct 202656USD 7.41-2.4%
25 Sep 202651USD 7.59-8.4%
18 Sep 202651USD 8.29-1.9%
11 Sep 202652USD 8.45-10.0%
04 Sep 202651USD 9.39+2.3%
28 Aug 202654USD 9.18-2.0%
21 Aug 202658USD 9.365+4.4%
Provisional evidence
News subjects
What is shaping the score
Market update519 stories · 64%
Earnings683 stories · 21%
Regulatory and legal502 stories · 14%
Source mix
Where the evidence comes from
GlobeNewswire504 stories · 29%
MarketBeat722 stories · 14%
Stock Titan502 stories · 14%
Benzinga571 stories · 7%
The Manila Times501 stories · 7%
AllSci501 stories · 7%
Investing.com501 stories · 7%
Recurring subjects
Subjects appearing most often
Life Sciences10Financial Markets4Finance3Earnings3
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
22 Jun50 neutral16 Oct 16:06
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 16 Oct 16:06 | 51 | -2 | 17/100 (-6) | 14 (-3) | Provisional |
| 07 Oct 23:59 | 53 | -3 | 23/100 (-11) | 17 (-1) | Provisional |
| 01 Oct 23:59 | 56 | +5 | 34/100 (+12) | 18 (+2) | Provisional |
| 30 Sep 23:59 | 51 | +0 | 22/100 (-1) | 16 (+1) | Provisional |
| 29 Sep 23:59 | 51 | +0 | 23/100 (-1) | 15 (-1) | Provisional |
| 28 Sep 23:59 | 51 | +0 | 24/100 (-3) | 16 (+4) | Provisional |
| 26 Sep 23:59 | 51 | +0 | 27/100 (-2) | 12 (+1) | Provisional |
| 25 Sep 23:59 | 51 | +1 | 29/100 (+12) | 11 (+1) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 14 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Earnings2 stories
0.0%98.9%
Market update1 story
0.0%1.1%
Each side uses the same scale: 0–98.9% of the retained directional evidence.
Where the influence comes from
82.9%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Market updateNot used in direction
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 07 Oct 2026 11:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Arvinas, Inc. will present novel biomarker data from a Phase 1 clinical trial of its investigational drug, ARV-102, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders. ARV-102 is a PROTAC LRRK2 degrader designed to treat Parkinson's disease. The data will be …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Arvinas, Inc. will present novel biomarker data from a Phase 1 clinical trial of its investigational drug, ARV-102, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders. ARV-102 is a PROTAC LRRK2 degrader designed to treat Parkinson's disease. The data will be shared in both oral and e-poster presentations, detailing oculomotor and biomarker findings from the study.
- Published
- 01 Oct 2026 20:01
- News subject
- Regulatory and legal
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Life Sciences
72/100 tone
Arvinas (NASDAQ:ARVN) shares rose 6.3% during midday trading on Wednesday, though trading volume was significantly below average. The company recently reported a strong quarterly beat with revenue up 1,014.7% year over year and EPS of $2.58. Analysts maintain a "Hold" rating with a consen…
81.8% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Arvinas (NASDAQ:ARVN) shares rose 6.3% during midday trading on Wednesday, though trading volume was significantly below average. The company recently reported a strong quarterly beat with revenue up 1,014.7% year over year and EPS of $2.58. Analysts maintain a "Hold" rating with a consensus price target of $14.55.
- Published
- 01 Oct 2026 09:51
- News subject
- Earnings
- Why this score
- Positive market reaction, Large positive market reaction, Operating growth
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 55/100
- 30-day weight
- 81.8% of directional evidence · 15.3d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
60/100 tone
Bank of America Corp DE has acquired 252,939 shares of Arvinas, Inc. (NASDAQ:ARVN), valued at approximately $2.1 million, representing 0.39% of the company. Institutional investors now own 95.19% of Arvinas. Analysts currently have a "Hold" rating on the stock with an average price target…
1.1% of directional evidence
Low story strength
Scoring detailsDirect company coverage
Bank of America Corp DE has acquired 252,939 shares of Arvinas, Inc. (NASDAQ:ARVN), valued at approximately $2.1 million, representing 0.39% of the company. Institutional investors now own 95.19% of Arvinas. Analysts currently have a "Hold" rating on the stock with an average price target of $14.55, despite the company reporting strong quarterly revenue and earnings that significantly exceeded estimates.
- Published
- 01 Oct 2026 07:57
- News subject
- Market update
- Why this score
- Institutional or insider buying
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 31/100
- 30-day weight
- 1.1% of directional evidence · 15.3d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Arvinas, Inc., a clinical-stage biotechnology company, announced the grant of an option to purchase 64,766 shares of common stock and 42,388 restricted stock units to a new employee. These awards were granted on September 28, 2026, under Nasdaq Listing Rule 5635(c)(4) and not through the …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Arvinas, Inc., a clinical-stage biotechnology company, announced the grant of an option to purchase 64,766 shares of common stock and 42,388 restricted stock units to a new employee. These awards were granted on September 28, 2026, under Nasdaq Listing Rule 5635(c)(4) and not through the company's stock incentive plan. The awards will vest over four years, subject to the employee's continued service.
- Published
- 30 Sep 2026 02:01
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.6d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
FinanceLife Sciences
—Unscored
Market updateNot used in direction
Arvinas enters immuno-oncology with HPK1 PROTAC degrader in Phase I/II trial
Arvinas, Inc. has initiated a Phase I/II trial for ARV-6723, an oral PROTAC degrader targeting HPK1, marking its entry into immuno-oncology. This drug aims to degrade the HPK1 protein, a negative regulator of immune activation, and is being evaluated as both monotherapy and in combination…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Arvinas, Inc. has initiated a Phase I/II trial for ARV-6723, an oral PROTAC degrader targeting HPK1, marking its entry into immuno-oncology. This drug aims to degrade the HPK1 protein, a negative regulator of immune activation, and is being evaluated as both monotherapy and in combination with pembrolizumab for advanced solid tumors. ARV-6723 is the first HPK1 PROTAC degrader to enter clinical development in the US, expanding Arvinas's PROTAC pipeline.
- Published
- 29 Sep 2026 19:57
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Life Sciences
—Unscored
Market updateNot used in direction
Arvinas doses first patient in ARV-6723 cancer trial
Arvinas Inc. (NASDAQ:ARVN) has announced the dosing of the first patient in its Phase 1/2 clinical trial for ARV-6723, an oral drug targeting hematopoietic progenitor kinase 1 (HPK1) in advanced solid tumors. This marks Arvinas' first immuno-oncology clinical candidate and the first HPK1 …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Arvinas Inc. (NASDAQ:ARVN) has announced the dosing of the first patient in its Phase 1/2 clinical trial for ARV-6723, an oral drug targeting hematopoietic progenitor kinase 1 (HPK1) in advanced solid tumors. This marks Arvinas' first immuno-oncology clinical candidate and the first HPK1 PROTAC degrader to enter clinical trials in the U.S. Preclinical studies showed ARV-6723's ability to degrade HPK1, enhance immune activity, and demonstrate antitumor effects both as a monotherapy and in combination with an immune checkpoint inhibitor.
- Published
- 28 Sep 2026 19:57
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 28 Sep 2026 11:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Regulatory and legalNot used in direction
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical
Arvinas, Inc. has dosed the first patient in its Phase 1/2 clinical trial for ARV-6723, an investigational oral PROTAC designed to degrade HPK1 in advanced solid tumors. This marks Arvinas' first immuno-oncology candidate and the first HPK1 PROTAC degrader to enter clinical trials in the …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Arvinas, Inc. has dosed the first patient in its Phase 1/2 clinical trial for ARV-6723, an investigational oral PROTAC designed to degrade HPK1 in advanced solid tumors. This marks Arvinas' first immuno-oncology candidate and the first HPK1 PROTAC degrader to enter clinical trials in the U.S. Preclinical studies showed ARV-6723's potential to enhance immune activity and demonstrate antitumor activity, including in models resistant to immune checkpoint inhibitors.
- Published
- 28 Sep 2026 10:31
- News subject
- Regulatory and legal
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.2d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Life Sciences
—Unscored
Market updateNot used in direction
A cancer drug designed to remove a protein that limits immune activity enters human testing.
Arvinas (ARVN) has initiated a Phase 1/2 clinical trial for ARV-6723, its first immuno-oncology candidate, designed to degrade the HPK1 protein which restricts immune activation. The oral drug will be evaluated for safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor acti…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Arvinas (ARVN) has initiated a Phase 1/2 clinical trial for ARV-6723, its first immuno-oncology candidate, designed to degrade the HPK1 protein which restricts immune activation. The oral drug will be evaluated for safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity in adults with advanced solid tumors, initially as monotherapy and later in combination with pembrolizumab. Preclinical studies showed ARV-6723 effectively enhanced immune activity and demonstrated antitumor effects, including in models resistant to current immune checkpoint inhibitors.
- Published
- 28 Sep 2026 10:31
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Life Sciences
—Unscored
Market updateNot used in direction
ARVN News | ARVINAS INC (NASDAQ:ARVN)
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 26 Sep 2026 00:01
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
57/100 tone
Arvinas Inc. reported significant progress in Q2 2026, including the FDA approval of its PROTAC degrader Vepanu, an out-licensing agreement with Rigel Pharmaceuticals, and a strategic decision to seek a partner for its KRAS G12D program. The company is now focusing on advancing its Phase …
17.1% of directional evidence
Low story strength
Scoring detailsDirect company coverage
Arvinas Inc. reported significant progress in Q2 2026, including the FDA approval of its PROTAC degrader Vepanu, an out-licensing agreement with Rigel Pharmaceuticals, and a strategic decision to seek a partner for its KRAS G12D program. The company is now focusing on advancing its Phase 1 clinical programs for ARV393 (BCL6 degradation), ARV027 (polyglutamine repeat androgen receptors), and ARV102 (LRRK2 degradation). Arvinas ended the quarter with $567.9 million in cash, reported $249.7 million in total revenue, and expects its cash runway to last into the second half of 2028.
- Published
- 25 Sep 2026 15:26
- News subject
- Earnings
- Why this score
- Fda Approval
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 33/100
- 30-day weight
- 17.1% of directional evidence · 21.0d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinanceLife Sciences
—Unscored
Market updateNot used in direction
Arvinas (NASDAQ: ARVN) director plans stock sale under SEC resale rule
Arvinas director Sunil Agarwal plans to sell up to 23,105 shares of common stock under SEC Rule 144. The shares, valued at $196,242.32, are from a stock option exercise and are scheduled for sale on September 22, 2026, through Morgan Stanley Smith Barney LLC on NASDAQ. This filing indicat…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Arvinas director Sunil Agarwal plans to sell up to 23,105 shares of common stock under SEC Rule 144. The shares, valued at $196,242.32, are from a stock option exercise and are scheduled for sale on September 22, 2026, through Morgan Stanley Smith Barney LLC on NASDAQ. This filing indicates a neutral impact and sentiment, detailing the transaction specifics and providing definitions for relevant financial terms.
- Published
- 22 Sep 2026 22:22
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 23.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
FinanceFinancial MarketsLife Sciences
—Unscored
EarningsNot used in direction
ARVN Q2 2026 Earnings: EPS Swings to $2.58, Beating Estimates by a Wide Margin - Earnings Surprise Report
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 21 Sep 2026 14:33
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 25.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Earlier company news
ARVN news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 93 older ARVN headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to ARVN, but the headline and available text are not mainly about Arvinas Inc. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of ARVN sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.